Search Results - "HØGDALL, E"

OP14.01: Evaluating the ADNEX model for differentiating between benign and malignant adnexal masses in Denmark by Karlsen, N. S., Sakse, A., Høgdall, C. K., Høgdall, E. V., Karlsen, M. A., Dreisler, E.

Get full text

Next Generation Sequencing in routine diagnostics of mature non‐Hodgkin’s lymphomas. A single‐center real‐life data study by Breinholt, M. F., Schejbel, L., Gang, A. O., Nielsen, T. H., Pedersen, L. M., Høgdall, E., Nørgaard, P.

Get full text

Hepatic arterial infusion (HAI) of oxaliplatin with capecitabine in first line treatment of patients (pts) with liver limited metastases from colorectal cancer (LLmCRC) by Vittrup, B V, Nørgaard, H H, Bergenfeldt, M, Larsen, F O, Høgdall, E, Johansen, J S, Sidenius Johansen, J S, Hermann, H K, Nielsen, D L

Get full text

Gene expression profile (GEP) and survival among patients with advanced ovarian cancer by Høgdall, E., Høgdall, C.K., Vo, P.-T., Zhou, W., Huang, L., Marton, M., Keefe, S.M., Busch-Sørensen, M., Sørensen, S.M., Georgsen, J., Mejlgaard, E., Nedergaard, L., Steiniche, T.

Get full text

274 Development of a novel marker for detection of degradation and formation of fibronectin in cancer ex vivo models by Bager, C.L, Bay-Jensen, A.C, Leeming, D.J, Gudmann, N.S, Karsdal, M, Balslev, I, Christiansen, A.P, Høgdall, E, He, Y

Get full text

275 ECM degradation products are released from kidney tumor tissue and adjacent tissue by Bager, C.L, Willumsen, N, Quilez-Alvarez, A, Bay-Jensen, A.C, Leeming, D.J, Karsdal, M, Christiansen, A.P, Balslev, I, Høgdall, E

Get full text

PD-L1 diagnostics in the neoadjuvant setting: implications of intratumoral heterogeneity of PD-L1 expression in triple negative breast cancer for assessment in small biopsies by Stovgaard, E. S., Bokharaey, M., List-Jensen, K., Roslind, A., Kümler, I., Høgdall, E., Nielsen, D., Balslev, E.

“…Purpose PD-L1 expression is a predictive biomarker for anti-PD-L1 immunotherapy in triple negative breast cancer (TNBC). In the neoadjuvant setting,…”
Get full text

P02-32 Ascites from women with ovarian carcinoma contains an elevated in vitro IGF-bioactivity as compared with serum by Thomsen, J, Ørtoft, G, Espelund, U, Høgdall, C, Høgdall, E, Frystyk, J

Get full text

Induction chemotherapy with capecitabine and oxaliplatin followed by chemoradiotherapy before total mesorectal excision in patients with locally advanced rectal cancer by Schou, J.V., Larsen, F.O., Rasch, L., Linnemann, D., Langhoff, J., Høgdall, E., Nielsen, D.L., Vistisen, K., Fromm, A., Jensen, B.V.

“…Preoperative chemoradiation in patients with locally advanced rectal cancer has no impact on overall survival (OS) and distant recurrences. The aim of the…”
Get full text

Genomic alterations accompanying tumour evolution in colorectal cancer: tracking the differences between primary tumours and synchronous liver metastases by whole-exome sequencing by Mogensen, M B, Rossing, M, Østrup, O, Larsen, P N, Heiberg Engel, P J, Jørgensen, L N, Hogdall, E V, Eriksen, J, Ibsen, P, Jess, P, Grauslund, M, Nielsen, H J, Nielsen, F C, Vainer, B, Osterlind, K

“…Colorectal cancer (CRC) patients with metastatic disease can become cured if neoadjuvant treatment can enable a resection. The search for predictive biomarkers…”
Get full text

Genomic landscape of treatment refractory metastatic colorectal cancer by Eefsen, R L, Simonsen, K S, Grundtvig, P, Klarskov, L, Chen, I M, Høgdall, D, Jensen, B V, Lorentzen, T, Poulsen, T S, Theile, S, Nielsen, D, Høgdall, E

“…Metastatic colorectal cancer (mCRC) is a complex and heterogeneous disease with few standard and targeted treatment options. Next-generation sequencing of…”
Get more information

Quantification of fibronectin as a method to assess ex vivo extracellular matrix remodeling by Bager, C.L., Gudmann, N., Willumsen, N., Leeming, D.J., Karsdal, M.A., Bay-Jensen, A.C., Høgdall, E., Balslev, I., He, Y.

“…Altered architecture, composition and quality of the extracellular matrix (ECM) are pathological hallmarks of several inflammatory and fibro-proliferative…”
Get full text

Aspirin, Nonaspirin Nonsteroidal Anti-inflammatory Drug, and Acetaminophen Use and Risk of Invasive Epithelial Ovarian Cancer: A Pooled Analysis in the Ovarian Cancer Association Consortium by TRABERT, Britton, NESS, Roberta B, RISCH, Harvey A, ROSSING, Mary Anne, DOHERTY, Jennifer A, GOODMAN, Marc T, LURIE, Galina, KJAER, Susanne K, HOGDALL, Estrid, JENSEN, Allan, CRAMER, Daniel W, TERRY, Kathryn L, LO-CIGANIC, Wei-Hsuan, VITONIS, Allison, BANDERA, Elisa V, OLSON, Sara, KING, Melony G, CHANDRAN, Urmila, ANTON-CULVER, Hoda, ZIOGAS, Argyrios, MENON, Usha, GAYTHER, Simon A, RAMUS, Susan J, MURPHY, Megan A, GENTRY-MAHARAJ, Aleksandra, WU, Anna H, PEARCE, Celeste Leigh, PIKE, Malcolm C, BERCHUCK, Andrew, SCHILDKRAUT, Joellen M, WENTZENSEN, Nicolas, GOODE, Ellen L, POOLE, Elizabeth M, BRINTON, Louise A, WEBB, Penelope M, NAGLE, Christina M, JORDAN, Susan J

“…Regular aspirin use is associated with reduced risk of several malignancies. Epidemiologic studies analyzing aspirin, nonaspirin nonsteroidal anti-inflammatory…”
Get full text

Soluble urokinase plasminogen activator receptor measurements: influence of sample handling by Riisbro, R, Christensen, I J, Høgdall, C, Brünner, N, Høgdall, E

“…The influence of sample handling on soluble urokinase plasminogen activator receptor (suPAR) concentrations in serum and EDTA plasma was studied in 16 healthy…”
Get more information

Oral administration of irinotecan in patients with solid tumors: an open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics by Kümler, I., Sørensen, P. Grundtvig, Palshof, J., Høgdall, E., Skovrider-Ruminski, W., Theile, S., Fullerton, A., Nielsen, P. G., Jensen, B. Vittrup, Nielsen, D. L.

“…Background Oral drug formulations have several advantages compared to intravenous formulation. Apart from patient convenience and favorable pharmacoeconomics,…”
Get full text

Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium by Nagle, C M, Dixon, S C, Jensen, A, Kjaer, S K, Modugno, F, deFazio, A, Fereday, S, Hung, J, Johnatty, S E, Fasching, P A, Beckmann, M W, Lambrechts, D, Vergote, I, Van Nieuwenhuysen, E, Lambrechts, S, Risch, H A, Rossing, M A, Doherty, J A, Wicklund, K G, Chang-Claude, J, Goodman, M T, Ness, R B, Moysich, K, Heitz, F, du Bois, A, Harter, P, Schwaab, I, Matsuo, K, Hosono, S, Goode, E L, Vierkant, R A, Larson, M C, Fridley, B L, Høgdall, C, Schildkraut, J M, Weber, R P, Cramer, D W, Terry, K L, Bandera, E V, Paddock, L, Rodriguez-Rodriguez, L, Wentzensen, N, Yang, H P, Brinton, L A, Lissowska, J, Høgdall, E, Lundvall, L, Whittemore, A, McGuire, V, Sieh, W, Rothstein, J, Sutphen, R, Anton-Culver, H, Ziogas, A, Pearce, C L, Wu, A H, Webb, P M

“…Background: Observational studies have reported a modest association between obesity and risk of ovarian cancer; however, whether it is also associated with…”
Get full text

Do CA125 response criteria overestimate tumour response in second-line treatment of epithelial ovarian carcinoma? by GRONLUND, B, HANSEN, H. H, HØGDALL, C, HOGDALL, E. V. S, ENGELHOLM, S. A

“…Recent studies indicate that cancer antigen 125 (CA125) response criteria tend to overestimate a tumour reduction measured by standard WHO response criteria in…”
Get full text

Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study by Köbel, M, Madore, J, Ramus, S J, Clarke, B A, Pharoah, P D P, Deen, S, Bowtell, D D, Odunsi, K, Menon, U, Morrison, C, Lele, S, Bshara, W, Sucheston, L, Beckmann, M W, Hein, A, Thiel, F C, Hartmann, A, Wachter, D L, Anglesio, M S, Høgdall, E, Jensen, A, Høgdall, C, Kalli, K R, Fridley, B L, Keeney, G L, Fogarty, Z C, Vierkant, R A, Liu, S, Cho, S, Nelson, G, Ghatage, P, Gentry-Maharaj, A, Gayther, S A, Benjamin, E, Widschwendter, M, Intermaggio, M P, Rosen, B, Bernardini, M Q, Mackay, H, Oza, A, Shaw, P, Jimenez-Linan, M, Driver, K E, Alsop, J, Mack, M, Koziak, J M, Steed, H, Ewanowich, C, DeFazio, A, Chenevix-Trench, G, Fereday, S, Gao, B, Johnatty, S E, George, J, Galletta, L, Goode, E L, Kjær, S K, Huntsman, D G, Fasching, P A, Moysich, K B, Brenton, J D, Kelemen, L E

“…Background: Folate receptor 1 (FOLR1) is expressed in the majority of ovarian carcinomas (OvCa), making it an attractive target for therapy. However, clinical…”
Get full text

Increased risk of ovarian cancer in integrin β3 Leu33Pro homozygotes by Bojesen, S E, Kjær, S K, Høgdall, E V S, Thomsen, B L, Høgdall, C K, Blaakær, J, Tybjærg-Hansen, A, Nordestgaard, B G

“…We previously demonstrated that integrin β3 Leu33Pro homozygotes have an increased risk of cancer, possibly most pronounced for ovarian cancer. We now test the…”
Get full text

Does the use of diagnostic PET/CT cause stage migration in patients with primary advanced ovarian cancer? by Risum, S, Høgdall, C, Loft, A, Berthelsen, A.K, Høgdall, E, Nedergaard, L, Lundvall, L, Engelholm, S.A

“…Abstract Objective To investigate if the use of diagnostic FDG-PET/CT leads to stage migration in patients with advanced ovarian cancer and to evaluate the…”
Get full text